6
Views
8
CrossRef citations to date
0
Altmetric
Research

Overview: Cardiovascular & Renal; Cyclic nucleotide phosphodiesterase inhibitors

Pages 417-430 | Published online: 29 Feb 2008
 

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) hydrolyse cyclic nucleotides to their inactive form (5' nucleotides), and thereby play an important role in cellular signalling mechanisms. These enzymes can be classed into seven families (or isozymes/isoenzymes) on the basis of their amino acid sequence, substrate specificity and sensitivity to pharmacological agents. This article reviews each PDE family in turn and analyses the patent literature in each area. Specific attention has been placed on those patents which disclose compounds reported to be useful for the treatment of cardiovascular diseases including thrombosis and atherosclerosis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.